KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Exchange Rate Effect: 2012-2025

Historic Exchange Rate Effect for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Sep 2025 value amounting to $203,000.

  • Jazz Pharmaceuticals' Exchange Rate Effect fell 93.39% to $203,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 76.15%. This contributed to the annual value of -$1.7 million for FY2024, which is 247.32% down from last year.
  • Jazz Pharmaceuticals' Exchange Rate Effect amounted to $203,000 in Q3 2025, which was down 95.61% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Exchange Rate Effect peaked at $4.9 million during Q4 2022, and registered a low of -$5.4 million during Q3 2022.
  • Its 3-year average for Exchange Rate Effect is $544,000, with a median of $203,000 in 2025.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Exchange Rate Effect crashed by 2,332.35% in 2024, and later soared by 709.22% in 2025.
  • Jazz Pharmaceuticals' Exchange Rate Effect (Quarterly) stood at -$1.4 million in 2021, then soared by 456.06% to $4.9 million in 2022, then slumped by 63.75% to $1.8 million in 2023, then crashed by 227.95% to -$2.3 million in 2024, then tumbled by 93.39% to $203,000 in 2025.
  • Its last three reported values are $203,000 in Q3 2025, $4.6 million for Q2 2025, and $1.7 million during Q1 2025.